S&P 500   3,980.97 (+0.25%)
DOW   32,463.41 (+0.70%)
QQQ   308.55 (-0.75%)
AAPL   158.61 (-1.02%)
MSFT   276.25 (-1.54%)
META   202.22 (-1.84%)
GOOGL   102.44 (-2.85%)
AMZN   97.43 (-0.71%)
TSLA   192.56 (+1.13%)
NVDA   264.28 (-1.31%)
NIO   8.93 (-1.54%)
BABA   85.74 (-1.33%)
AMD   95.87 (-2.12%)
T   18.86 (+1.34%)
F   11.52 (+0.09%)
MU   59.70 (-2.39%)
CGC   1.89 (-0.53%)
GE   93.02 (+1.81%)
DIS   94.97 (+0.95%)
AMC   4.36 (-2.46%)
PYPL   73.49 (-0.53%)
PFE   40.31 (-0.20%)
NFLX   329.17 (+0.24%)
S&P 500   3,980.97 (+0.25%)
DOW   32,463.41 (+0.70%)
QQQ   308.55 (-0.75%)
AAPL   158.61 (-1.02%)
MSFT   276.25 (-1.54%)
META   202.22 (-1.84%)
GOOGL   102.44 (-2.85%)
AMZN   97.43 (-0.71%)
TSLA   192.56 (+1.13%)
NVDA   264.28 (-1.31%)
NIO   8.93 (-1.54%)
BABA   85.74 (-1.33%)
AMD   95.87 (-2.12%)
T   18.86 (+1.34%)
F   11.52 (+0.09%)
MU   59.70 (-2.39%)
CGC   1.89 (-0.53%)
GE   93.02 (+1.81%)
DIS   94.97 (+0.95%)
AMC   4.36 (-2.46%)
PYPL   73.49 (-0.53%)
PFE   40.31 (-0.20%)
NFLX   329.17 (+0.24%)
S&P 500   3,980.97 (+0.25%)
DOW   32,463.41 (+0.70%)
QQQ   308.55 (-0.75%)
AAPL   158.61 (-1.02%)
MSFT   276.25 (-1.54%)
META   202.22 (-1.84%)
GOOGL   102.44 (-2.85%)
AMZN   97.43 (-0.71%)
TSLA   192.56 (+1.13%)
NVDA   264.28 (-1.31%)
NIO   8.93 (-1.54%)
BABA   85.74 (-1.33%)
AMD   95.87 (-2.12%)
T   18.86 (+1.34%)
F   11.52 (+0.09%)
MU   59.70 (-2.39%)
CGC   1.89 (-0.53%)
GE   93.02 (+1.81%)
DIS   94.97 (+0.95%)
AMC   4.36 (-2.46%)
PYPL   73.49 (-0.53%)
PFE   40.31 (-0.20%)
NFLX   329.17 (+0.24%)
S&P 500   3,980.97 (+0.25%)
DOW   32,463.41 (+0.70%)
QQQ   308.55 (-0.75%)
AAPL   158.61 (-1.02%)
MSFT   276.25 (-1.54%)
META   202.22 (-1.84%)
GOOGL   102.44 (-2.85%)
AMZN   97.43 (-0.71%)
TSLA   192.56 (+1.13%)
NVDA   264.28 (-1.31%)
NIO   8.93 (-1.54%)
BABA   85.74 (-1.33%)
AMD   95.87 (-2.12%)
T   18.86 (+1.34%)
F   11.52 (+0.09%)
MU   59.70 (-2.39%)
CGC   1.89 (-0.53%)
GE   93.02 (+1.81%)
DIS   94.97 (+0.95%)
AMC   4.36 (-2.46%)
PYPL   73.49 (-0.53%)
PFE   40.31 (-0.20%)
NFLX   329.17 (+0.24%)
NASDAQ:SRTS

Sensus Healthcare - SRTS Competitors

$5.14
+0.11 (+2.19%)
(As of 03/27/2023 12:21 PM ET)
Add
Compare
Today's Range
$5.00
$5.16
50-Day Range
$4.96
$9.49
52-Week Range
$4.80
$15.25
Volume
62,279 shs
Average Volume
232,689 shs
Market Capitalization
$85.38 million
P/E Ratio
3.52
Dividend Yield
N/A
Price Target
$16.83

SRTS vs. NVCN, STIM, APYX, NPCE, LYRA, LUCD, BVS, AKLI, PDEX, and RVP

Should you be buying Sensus Healthcare stock or one of its competitors? The main competitors of Sensus Healthcare include Neovasc (NVCN), Neuronetics (STIM), Apyx Medical (APYX), NeuroPace (NPCE), Lyra Therapeutics (LYRA), Lucid Diagnostics (LUCD), Bioventus (BVS), Akili (AKLI), Pro-Dex (PDEX), and Retractable Technologies (RVP). These companies are all part of the "surgical & medical instruments" industry.

Sensus Healthcare vs.

Neovasc (NASDAQ:NVCN) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings.

Neovasc received 223 more outperform votes than Sensus Healthcare when rated by MarketBeat users. However, 68.63% of users gave Sensus Healthcare an outperform vote while only 65.03% of users gave Neovasc an outperform vote.

CompanyUnderperformOutperform
NeovascOutperform Votes
398
65.03%
Underperform Votes
214
34.97%
Sensus HealthcareOutperform Votes
175
68.63%
Underperform Votes
80
31.37%

Sensus Healthcare has a net margin of 54.44% compared to Neovasc's net margin of -1,077.37%. Sensus Healthcare's return on equity of 25.55% beat Neovasc's return on equity.

Company Net Margins Return on Equity Return on Assets
Neovasc -1,077.37% -78.98% -56.59%
Sensus Healthcare 54.44% 25.55% 20.84%

Neovasc has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Comparatively, Sensus Healthcare has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.

Sensus Healthcare has a consensus price target of $16.83, indicating a potential upside of 234.66%. Given Sensus Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe Sensus Healthcare is more favorable than Neovasc.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neovasc
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Sensus Healthcare
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Neovasc had 1 more articles in the media than Sensus Healthcare. MarketBeat recorded 3 mentions for Neovasc and 2 mentions for Sensus Healthcare. Sensus Healthcare's average media sentiment score of 1.89 beat Neovasc's score of 0.41 indicating that Sensus Healthcare is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neovasc
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Sensus Healthcare
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

1.6% of Neovasc shares are owned by institutional investors. Comparatively, 36.3% of Sensus Healthcare shares are owned by institutional investors. 0.5% of Neovasc shares are owned by insiders. Comparatively, 16.4% of Sensus Healthcare shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Sensus Healthcare has higher revenue and earnings than Neovasc. Neovasc is trading at a lower price-to-earnings ratio than Sensus Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neovasc$2.55 million32.11-$24.89 million-$12.29-2.43
Sensus Healthcare$44.53 million1.88$24.24 million$1.463.45

Summary

Sensus Healthcare beats Neovasc on 14 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRTS vs. The Competition

MetricSensus HealthcareSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$83.55M$3.29B$4.22B$5.86B
Dividend YieldN/A3.14%5.98%4.53%
P/E Ratio3.4599.29141.3315.64
Price / Sales1.8826.133,210.0654.29
Price / Cash17.4243.7526.75103.95
Price / Book3.204.194.154.94
Net Income$24.24M$56.99M$113.22M$190.12M
7 Day Performance-1.95%5.23%114.49%4.26%
1 Month Performance-27.94%-2.80%107.35%-3.28%
1 Year Performance-56.07%-26.07%110.39%-18.17%

Sensus Healthcare Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVCN
Neovasc
0.9884 of 5 stars
$29.71
+1.2%
N/A+176.7%$81.41M$2.55M-2.4249Upcoming Earnings
Analyst Report
Short Interest ↑
STIM
Neuronetics
2.3157 of 5 stars
$2.92
-7.6%
$9.67
+231.1%
-6.3%$79.48M$65.21M-2.12175Short Interest ↑
Gap Up
APYX
Apyx Medical
1.8914 of 5 stars
$2.70
+3.1%
$6.00
+122.2%
-53.0%$93.42M$44.51M-4.03272Short Interest ↑
NPCE
NeuroPace
1.6451 of 5 stars
$3.76
+5.6%
$9.17
+143.8%
-51.2%$94.38M$45.52M-1.96166
LYRA
Lyra Therapeutics
2.3094 of 5 stars
$2.06
-3.7%
$17.50
+748.4%
-57.6%$65.66M$280,000.00-0.8553Upcoming Earnings
Short Interest ↓
Gap Down
LUCD
Lucid Diagnostics
1.6765 of 5 stars
$1.47
-4.5%
$7.82
+432.0%
-53.5%$63.78M$380,000.00-1.022,021Short Interest ↓
BVS
Bioventus
1.838 of 5 stars
$1.34
-5.0%
$6.75
+403.7%
-89.9%$103.78M$430.90M-0.651,200Upcoming Earnings
Gap Up
AKLI
Akili
1.8924 of 5 stars
$1.33
+6.4%
$3.75
+182.0%
N/A$103.87M$320,000.000.00N/AGap Down
PDEX
Pro-Dex
0 of 5 stars
$16.86
-2.0%
$30.00
+77.9%
-5.6%$59.68M$42.04M16.37117Short Interest ↑
RVP
Retractable Technologies
0 of 5 stars
$1.77
flat
N/AN/A$58.30M$141.60M2.01N/AAnalyst Report
Gap Down
This page (NASDAQ:SRTS) was last updated on 3/27/2023 by MarketBeat.com Staff